Plasma Lipid Profiling Identifies Phosphatidylcholine 34:3 and Triglyceride 52:3 as Potential Markers Associated with Disease Severity and Oxidative Status in Chronic Obstructive Pulmonary Disease

Amel Ben Anes1, Hela Ben Nasr1,2, Zouhair Tabka1, Oussama Tabka1, Monia Zaouali1, Karim Chahed1,3
1Research Laboratory (LR19ES09): Exercise Physiology and Pathophysiology - From the Integrated to the Molecular Biology, Medicine and Health, Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia
2Higher Institute of Nursing Sciences, Sousse, Tunisia
3Faculty of Sciences of Sfax, Sfax, Tunisia

Tóm tắt

To identify plasma alterations in lipid species in patients with chronic obstructive pulmonary disease (COPD), as well as, relationships with smoking status, oxidative and inflammatory markers. Plasma was obtained from 100 patients with COPD and 120 healthy controls. Pulmonary function was assessed by plethysmography. Serum levels of IL-6 and TNF-α were determined by ELISA. Oxidative stress parameters were measured using standard methods. Lipids were extracted then analyzed by Matrix-Assisted Laser Desorption and Ionization Time-Of-Flight Mass Spectrometry (MALDI-TOF-TOF-MS). More than 40 lipid compounds were identified within plasma samples. Among these 19 lipid species including plasmalogens (PC O-), phosphatidylcholines (PC), and triglycerides (TG) were significantly altered in COPD. A decreased expression of PC O- (36:1, 36:2, 36:3, 36:4, 38:4, 38:5) species was found in patients with different severities compared to healthy controls. There was also a decrease in PC (34:3, 36:0, 36:4, 36:5, 40:6, 40:7) species in COPD patients. PC (34:3) levels were positively correlated with disease progression and pulmonary function decline (forced expiratory volume in 1 s (FEV1)) (r = 0.84, p < 0.001) and inversely correlated with thiobarbituric acid-reactive substances (TBARS) (r = − 0.77, p < 0.001). TG (50:0, 50:1, 52:1, 52:2, 52:3, 52:4, 54:4) species were altered in COPD patients and in those with advanced disease stages. Significant correlations between FEV1, TBARS, peroxynitrite, and TG (52:3) were found among COPD patients (r = − 0.69; r = 0.86; r = 0.77, p < 0.001, respectively). PC (34:3) and TG (52:3) could be potential lipid signatures of COPD that correlate with altered pulmonary function and oxidative status.

Tài liệu tham khảo

Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095–2128. https://doi.org/10.1016/S0140-6736(12)61728-0 GOLD: Global Initiative for Chronic Obstructive Lung Disease (2019) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease Report. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed April 28 2021 Kirkham P, Rahman I (2006) Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther 111(2):476–494. https://doi.org/10.1016/j.pharmthera.2005.10.015 Barnes PJ (2004) Alveolar macrophages in chronic obstructive pulmonary disease (COPD). Cell Mol Biol (Noisy-le-grand) 50 Online Pub:OL627–37 Braverman NE, Moser AB (2012) Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta 9:1442–1452. https://doi.org/10.1016/j.bbadis.2012.05.008 Nambiar S, Bong How S, Gummer J et al (2020) Metabolomics in chronic lung diseases. Respirology 25(2):139–148. https://doi.org/10.1111/resp.13530 Grothe J, Riethmüller J, Tschürtz SM et al (2015) Plasma phosphatidylcholine alterations in cystic fibrosis patients: impaired metabolism and correlation with lung function and inflammation. Cell Physiol Biochem 35(4):1437–1453. https://doi.org/10.1159/000373964 Guerrera IC, Astarita G, Jais JP et al (2009) A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients. PLoS ONE 4(11):e7735. https://doi.org/10.1371/journal.pone.0007735 Kertys M, Grendar M, Kosutova P et al (1866) (2020) Plasma based targeted metabolomic analysis reveals alterations of phosphatidylcholines and oxidative stress markers in guinea pig model of allergic asthma. Biochim Biophys Acta Mol Basis Dis 1:165572. https://doi.org/10.1016/j.bbadis.2019.165572 Agudelo CW, Kumley BK, Area-Gomez E et al (2020) Decreased surfactant lipids correlate with lung function in chronic obstructive pulmonary disease (COPD). PLoS ONE 15(2):e0228279. https://doi.org/10.1371/journal.pone.0228279 GOLD: Global Initiative for Chronic Obstructive Lung Disease. (2015) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease updated. https://fr.scribd.com/document/272609900/GOLD-Report-2015-Feb18-pdf. Accessed April 28, 2021 Ben Anes A, Ben Nasr H, Fetoui H et al (2016) Alteration in systemic markers of oxidative and antioxidative status in Tunisian patients with asthma: relationships with clinical severity and airflow limitation. J Asthma 53(3):227–237. https://doi.org/10.3109/02770903.2015.1087559 Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226(1):497–509 Serna J, García-Seisdedos D, Alcázar A et al (2015) Quantitative lipidomic analysis of plasma and plasma lipoproteins using MALDI-TOF mass spectrometry. Chem Phys Lipids 189:7–18. https://doi.org/10.1016/j.chemphyslip.2015.05.005 Putman E, van Golde LM, Haagsman HP (1997) Toxic oxidant species and their impact on the pulmonary surfactant system. Lung 175(2):75–103. https://doi.org/10.1007/pl00007561 Kuzmenko AI, Wu H, Bridges JP et al (2004) Surfactant lipid peroxidation damages surfactant protein A and inhibits interactions with phospholipid vesicles. J Lipid Res 45(6):1061–1068. https://doi.org/10.1194/jlr.M300360-JLR200 Wang-Sattler R, Yu Y, Mittelstrass K et al (2008) Metabolic profiling reveals distinct variations linked to nicotine consumption in humans–first results from the KORA study. PLoS ONE 3(12):e3863. https://doi.org/10.1371/journal.pone.0003863 Beckett CS, Kell PJ, Creer MH et al (2007) Phospholipase A2-catalyzed hydrolysis of plasmalogen phospholipids in thrombin-stimulated human platelets. Thromb Res 120(2):259–268. https://doi.org/10.1016/j.thromres.2006.09.005 Wallner S, Schmitz G (2011) Plasmalogens the neglected regulatory and scavenging lipid species. Chem Phys Lipids 164(6):573–589. https://doi.org/10.1016/j.chemphyslip.2011.06.008 Hahnel D, Beyer K, Engelmann B (1999) Inhibition of peroxyl radical-mediated lipid oxidation by plasmalogen phospholipids and alpha-tocopherol. Free Radic Biol Med 27(9–10):1087–1094. https://doi.org/10.1016/s0891-5849(99)00142-2 Zoeller RA, Grazia TJ, LaCamera P et al (2002) Increasing plasmalogen levels protects human endothelial cells during hypoxia. Am J Physiol Heart Circ Physiol 283(2):H671–H679. https://doi.org/10.1152/ajpheart.00524.2001 Rüdiger M, von Baehr A, Haupt R et al (2000) Preterm infants with high polyunsaturated fatty acid and plasmalogen content in tracheal aspirates develop bronchopulmonary dysplasia less often. Crit Care Med 28(5):1572–1577. https://doi.org/10.1097/00003246-200005000-00052 Titz B, Luettich K, Leroy P et al (2016) Alterations in serum polyunsaturated fatty acids and eicosanoids in patients with mild to moderate Chronic Obstructive Pulmonary Disease (COPD). Int J Mol Sci 17(9):1583. https://doi.org/10.3390/ijms17091583 Xuan L, Han F, Gong L et al (2018) Association between chronic obstructive pulmonary disease and serum lipid levels: a meta-analysis. Lipids Health Dis 17(1):263. https://doi.org/10.1186/s12944-018-0904-4 Torday JS, Torday DP, Gutnick J et al (2001) Biologic role of fetal lung fibroblast triglycerides as antioxidants. Pediatr Res 49(6):843–849. https://doi.org/10.1203/00006450-200106000-00021 Bailey AP, Koster G, Guillermier C et al (2015) Antioxidant role for lipid droplets in a stem cell niche of drosophila. Cell 163(2):340–353. https://doi.org/10.1016/j.cell.2015.09.020 Stegemann C, Pechlaner R, Willeit P et al (2014) Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation 129(18):1821–1831. https://doi.org/10.1161/CIRCULATIONAHA.113.002500 Tanaka H, Zaima N, Ito H et al (2013) Cilostazol inhibits accumulation of triglycerides in a rat model of carotid artery ligation. J Vasc Surg 58(5):1366–1374. https://doi.org/10.1016/j.jvs.2013.01.033 Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279(15):2610–2623. https://doi.org/10.1111/j.1742-4658.2012.08644.x Agudelo CW, Samaha G, Garcia-Arcos I (2020) Alveolar lipids in pulmonary disease. Rev Lipids Health Dis 19(1):122. https://doi.org/10.1186/s12944-020-01278-8 Weir JM, Wong G, Barlow CK et al (2013) Plasma lipid profiling in a large population-based cohort. J Lipid Res 54(10):2898–2908. https://doi.org/10.1194/jlr.P035808 Nana-Sinkam SP, Lee JD, Sotto-Santiago S et al (2007) Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am J Respir Crit Care Med 175(7):676–685. https://doi.org/10.1164/rccm.200605-724OC Vijayaraj P, Sivaprakasam C, Varthini LV et al (2014) In vitro exposure of tobacco specific nitrosamines decreases the rat lung phospholipids by enhanced phospholipase A2 activity. Toxicol In Vitro 28(6):1097–1105. https://doi.org/10.1016/j.tiv.2014.05.001 Granata F, Nardicchi V, Loffredo S et al (2009) Secreted phospholipases A(2): A proinflammatory connection between macrophages and mast cells in the human lung. Immunobiology 214(9–10):811–821. https://doi.org/10.1016/j.imbio.2009.06.006